

Type 2 Diabetes Open-label Trial Comparing a Once Daily Oral Medication to Insulin Glargine

Protocol	J2A-MC-GZGS
Ideal Patient Profile	Adult (18+) with T2DM and at least one CV risk factor and currently taking 1 – 3 approved oral antihyperglycemic medications (metformin \geq 1500 mg, SGLT2, or sulfonylurea)
Study Duration	Event-driven study with an estimated duration of approximately 2 years.
Visit Schedule	Weekly for 8 visits, transitioning to quarterly for study duration
Reimbursement	\$6328 plus actual travel and meal expenses
Inclusion Criteria:	
Medical Condition	T2DM with A1C 7.0 – 10.5% (LL 7.5% if taking sulfonylurea) and currently taking 1 – 3 approved medications (metformin \geq 1500 mg, SGLT2, or sulfonylurea)
Age	\geq 18 Years diagnosed w/ T2DM AND at least one CVD risk factor
BMI	\geq 27.0 kg/m ²
CVD Risk Factors:	
Coronary Heart Disease	MI, \geq 50 stenosis of major coronary artery, CAC \geq 300, stable angina (treated), asymptomatic cardiac ischemia, coronary angioplasty, CABG
Peripheral Artery Disease	Claudication, resting limb ischemia, \geq 50 stenosis of iliac / femoral / popliteal / subclavian arteries, ABI \leq 90, revasc/amputation, carotid stenosis \geq 70%, carotid revasc, abdominal AA
Cerebrovascular Disease	Ischemic stroke, $>$ 50 years of age with history of transient ischemic attack (TIA)
Chronic Kidney Disease	\geq 35 yrs old with history of CKD and eGFR $<$ 60mL/min/1.73m ² on Visit 1 and Visit 2
Congestive Heart Failure	\geq 50 years of age with CHF-NYHA class II or III
Key Exclusions:	
Medical Conditions	<ul style="list-style-type: none"> • T1DM • \geq1 episode of ketoacidosis, hyperosmolar state OR coma OR severe hypoglycemic unawareness within the last 6 months • Diagnosed with diabetic retinopathy an/or macular edema requiring treatment • Autoimmune disease likely to require glucocorticoid therapy in the next 12 mo
Obesity Related Exclusions	Obesity induced by other disorders (Cushing's disease, melanocortin 4 receptor deficiency, Prader-Willi, etc.
Con Meds (exclusionary)	<ul style="list-style-type: none"> • Use weight loss products (OTC or prescribed) within 3 months of visit 1 • Have used antihyperglycemics within 90 days of visit 1 or between visits 1 and 3 • Insulin therapy in the past 90 days prior to visit 1 • Chronic use of systemic glucocorticoid therapy ($>$14 days) within 30 days of visit 1 or between visits 1 and 3 (exceptions apply for topical, intraocular, intranasal, interphalangeal, or inhaled preparations)
Heart Disease or CVD	Has had in the past 90 days prior to visit 1 an acute MI OR Stroke OR hospitalization for congestive HF OR is diagnosed with congestive HF class IV
Kidney disease	eGFR $<$ 15ml/min/1.73m ² at visit 1
Gastrointestinal	Have a known clinically significant gastric emptying abnormality OR have undergone gastric bypass surgery OR undergone restrictive bariatric surgery OR chronically take drugs that directly affect GI motility
Liver disease	<ul style="list-style-type: none"> • Acute or chronic hepatitis or evidence of liver disease other than NAFLD • Positive test for hepatitis B or C test
Thyroid disease	<ul style="list-style-type: none"> • TSH outside range of 0.4 – 6.0 mUI/L at visit 1 • Serum calcitonin level of \geq20 ng/L at visit 1 if eGFR \geq60 mL/min/1.73 m² OR \geq35 ng/L at visit 1 if eGFR $<$60 mL/min/1.73 m²
Cancer	<ul style="list-style-type: none"> • Malignant neoplasms within past 5 years prior to screening with exceptions for basal or squamous skin cancer, stage 0 non-invasive cervical or prostate cancer • Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2